Intas Biopharmaceuticals

From Wikipedia, the free encyclopedia

Intas Biopharmaceuticals Ltd is an Indian multinational company headquartered in Ahmedabad, Gujarat. It was founded by Dr. Urmish Chudgar and is now headed by Hasmukh Chudgar. The Biologics unit (BU) of the company is located in Ahmedabad and it is one of the leading biosimilar product manufacturers in Asia. The unit (BU) has its own biopharmaceutical operations with a R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.[1]

Intas Biopharmaceuticals
TypePrivate
IndustryBiopharmaceuticals
Founded1984; 37 years ago (1984)
FounderDr. Urmish Chudgar
HeadquartersAhmedabad, Gujarat,
India
Area served
Worldwide
ProductsNeukine (GCSF)
Erykine (EPO)
Intalfa (IFN)
Pegasta (Peg GCSF)
Terifrac (Teriparatide)
Mabtas (Rituximab)
Folisurge (FSH)
RevenueIncrease ₹ 12,600 crore
(US$ 1.8 Billion) (2019)
Increase ₹ 1,248 crore
(US$ 204 Million) (2019)
Number of employees
8000+ (2021)
Websitewww.intaspharma.com

History[]

Intas Biopharmaceuticals Limited was set up in 1980 by Dr. Urmish Chudgar, a hematologist, as an independent biotechnology division of Intas Pharmaceuticals Ltd. It is a mid-sized generic formulation manufacturer located in Ahmedabad, India. The division was merged with the parent company Intas Pharmaceuticals Limited in 2013. Now, Intas Biopharmaceuticals is headed by Hasmukh Chudgar.

Present[]

The company faced an EU-GMP (Good Manufacturing Practice) audit in December 2006, to seek approval for a clinical trial of its biosimilar Filgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification.[2]

Apart from EU-GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.[3][4]

Products[]

In 2015, the company launched Accofil, a treatment for immune system disorders.[5][6]

Products of Intas Biopharmaceuticals and timeline

  • MabTas is Rituximab biosimilar of Intas

  • Intas manufactured Filgrastim (Accofil) registered in EU

  • Intas Biosimilar development timeline

Financials[]

The company had an annual revenue of $1.8 Billion (₹12,600 crore) in 2019 and a profit of $204 Million (₹1,248 crore) after taxes in the financial year 2019. The company's 69% of revenue came from international operations in the FY2019 while just 31% came from India.[7]

Acquisitions[]

References[]

  1. ^ "Intas mfg unit gets EU-GMP certification". The Economic Times. 13 June 2007.
  2. ^ "Intas mfg unit gets EU-GMP certification". The Economic Times. Retrieved 4 July 2021.
  3. ^ "About Us – Intas Pharmaceuticals Ltd". Retrieved 4 July 2021.
  4. ^ "Intas's Growth Driver : Biopharmaceuticals". NCK Pharma. 23 January 2015. Retrieved 4 July 2021.
  5. ^ "Intas Pharma launches its first biosimilar product Accofil in Europe". 23 February 2015. Retrieved 25 April 2019 – via The Economic Times.
  6. ^ Reporter, B. S. (23 February 2015). "Ahmedabad-based Intas Pharma launches biosimilar in EU". Retrieved 25 April 2019 – via Business Standard.
  7. ^ "Financials – Intas Pharmaceuticals Ltd". Retrieved 4 July 2021.
  8. ^ Dandekar, Vikas; Barman, Arijit (6 October 2016). "Intas buys Teva's UK & Ireland assets for $764 million to break into global top 20 generic players club". The Economic Times. Retrieved 8 May 2020.
  9. ^ Dandekar, Vikas; Barman, Arijit (7 October 2016). "Chudgars of Intas: A family that dreams big together". Retrieved 25 April 2019 – via The Economic Times.
  10. ^ "Intas Pharmaceuticals Completes Deal to Acquire Actavis". Moneycontrol. Retrieved 8 May 2020.
  11. ^ Bureau, Our. "Intas to acquire UK & Ireland generics businesses from Teva for £603 million". @businessline. Retrieved 4 July 2021.

External Links[]

Official site

Retrieved from ""